Reviews/P2Y12 Antiplatelets/Ticagrelor reduces MACE and mortality vs clopidogrel in ACS
Tca · P2Y12-TCA-01 · v2
One large, carefully blinded head-to-head trial [7] found that patients given ticagrelor after an acute coronary syndrome had fewer combined heart-attack, stroke and vascular-death events and fewer deaths from any cause than those given clopidogrel. The same direction of benefit appears when that trial is split by patient type [10] [16] [17] and in a separate real-world heart-attack group [1]. The weaker part of the claim is the survival benefit: it comes almost entirely from that single trial and does not reappear in older patients or in routine-care registries [13] [14] [8], where ticagrelor was sometimes linked to more deaths. A separate confirmatory trial in East Asian patients actually leaned numerically toward clopidogrel [20]. The panel treated the reduction in combined cardiovascular events as well supported, but judged the mortality half to rest on too narrow a base and to be contradicted in important groups, so it did not place the claim in the top tier.
The pivotal double-blind randomised trial [7] (N=18,624) reports the composite of vascular death, myocardial infarction or stroke at 9.8% with ticagrelor versus 11.7% with clopidogrel (hazard ratio 0.84, 95% CI 0.77 to 0.92, P<0.001) and death from any cause at 4.5% versus 5.9% (P<0.001). The direction holds in its NSTE-ACS subgroup (primary HR 0.83) [10], its diabetes subgroup (HR 0.88, 95% CI 0.76 to 1.03) [17] and its STE-ACS subgroup (HR 0.87, P=0.07) [16], and in an independent STEMI diabetes cohort where in-hospital MACCE was lower (HR 0.545, 95% CI 0.321 to 0.926) [1]. Against this, the SWEDEHEART elderly registry [13] shows ticagrelor with a higher death risk (HR 1.17, 95% CI 1.03 to 1.32) and similar ischaemic outcome (HR 0.97), the anticoagulated cohort [8] shows no MACE difference (aHR 1.02) with mortality aHR 1.24, and the confirmatory PHILO trial [20] numerically favoured clopidogrel (composite HR 1.47, 95% CI 0.88 to 2.44, not significant). The MACE component is more consistently supported across the corpus than the mortality component. The contested point: The division is over the mortality half of the claim: a single pivotal trial [7] shows an all-cause death reduction, but this is not reproduced and in places reverses in real-world elderly and anticoagulated populations [13] [8] [14], while the one confirmatory RCT [20] leaned toward clopidogrel. The evidence for reduced combined ischaemic events is broader than the evidence for reduced death.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from P2Y12 Antiplatelets, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The positive signal is dominated by a single trial: [7] PLATO and its five subanalyses [10] [11] [12] [16] [17] are not independent replications. Evidential weight is effectively one RCT re-cut, inflating apparent consistency.
The mortality half fails to replicate and in places reverses: SWEDEHEART elderly [13] shows ticagrelor with a 17% HIGHER death risk (HR 1.17, 95% CI 1.03-1.32), and the DOAC cohort [8] shows mortality aHR 1.24 with no MACE difference (aHR 1.02). The claim's mortality component is contradicted in important populations.
Where it remains uncertain. The mortality signal is largely confined to that one trial and reverses in the SWEDEHEART elderly registry (HR 1.17, 95% CI 1.03 to 1.32) [13] and the anticoagulated cohort (mortality aHR 1.24, MACE aHR 1.02) [8], while the confirmatory PHILO RCT [20] numerically favoured clopidogrel.
Aleatory
STE-ACS primary endpoint P=0.07 [16] and diabetes primary HR 0.88 with CI 0.76 to 1.03 crossing unity [17]; small event counts leave directional estimates compatible with no effect.
Epistemic
The all-cause death reduction is reported in one pivotal trial [7]; [10] [11] [12] [16] [17] are re-cuts of that same cohort, so the corpus holds no independent RCT confirming the mortality benefit.
Inferential
Real-world cohorts [13] [14] [8] channel clopidogrel to higher-risk multimorbid or older patients; residual confounding could bias the mortality and MACE estimates in either direction despite adjustment.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independent real-world STEMI cohort supporting MACE and cardiac death reduction
“the risk of in-hospital MACCE (HR = 0.545, 95% CI: 0.321-0.926, p = 0.025), Cardiac death (HR = 0.380, 95% CI: 0.149-0.971, p = 0.043) and NACE (HR = 0.728, 95% CI: 0.560-0.947, p = 0.018) was significantly lower in the ticagrelor group compared with the clopidogrel group”
Panel auditInternal validity: low · scope of inference: In-hospital outcomes in STEMI patients with diabetes and poor glycemic control undergoing primary PCI.Key limitations: retrospective, single program · in-hospital outcomes only · narrow diabetic poor-control subgroup
Primary MACE endpoint reduction in the pivotal 18,624-patient RCT
“The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001).”
Panel auditInternal validity: high · scope of inference: Patients admitted with ACS, with or without ST-segment elevation.Key limitations: higher non-CABG major bleeding · regional heterogeneity noted elsewhere
NSTE-ACS subgroup replicates both MACE and mortality reduction
“the primary endpoint was reduced with ticagrelor vs. clopidogrel [10.0 vs. 12.3%; hazard ratio (HR) 0.83; 95% confidence interval (CI) = 0.74-0.93], as was myocardial infarction (6.6 vs. 7.7%; HR 0.86; 95% CI = 0.74-0.99), cardiovascular death (3.7 vs. 4.9%; HR 0.77; 95% CI = 0.64-0.93), and all-cause death (4.3 vs. 5.8%; HR 0.76; 95% CI = 0.64-0.90)”
Panel auditInternal validity: high · scope of inference: NSTE-ACS subgroup of PLATO, with and without revascularization.Key limitations: subgroup of larger trial · retrospective categorisation · increased non-CABG bleeding
In the primary ≥80-year population the composite ischaemic outcome was similar and mortality was significantly higher with ticagrelor.
Panel auditInternal validity: low · scope of inference: Patients aged 80 years or older discharged after MI; a <80 subgroup favoured ticagrelor.Key limitations: observational · elderly only · opposite direction in younger patients · residual confounding
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A strong pivotal RCT carries the broad ACS claim, but single-trial dependence for mortality and non-replication in elderly and real-world populations keep it below the Established threshold.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory RCT of mortality benefit. The survival component rests on one trial [7]; the only confirmatory RCT in the corpus [20] was underpowered and non-significant. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered randomised double-blind trial of ticagrelor versus clopidogrel in ACS with all-cause mortality as a pre-specified endpoint, outside the original trial population.
Open question: Is the all-cause mortality reduction reproducible outside the single pivotal trial? Why it is still open: The death benefit is reported only in [7] and its non-independent re-cuts; the one confirmatory RCT [20] was non-significant and the registries [13] [14] [8] do not reproduce it.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19